Epithelial Ovarian Cancer Market Report 2026

The epithelial ovarian cancer market size has grown rapidly in recent years. It will grow from $2.41 billion in 2025 to $2.8 billion in 2026 at a compound annual growth rate (CAGR) of 16.2%. The growth in the historic period can be attributed to late-stage diagnosis prevalence, chemotherapy usage, aging female population, oncology infrastructure growth, clinical trial expansion.

The epithelial ovarian cancer market size is expected to see rapid growth in the next few years. It will grow to $5.03 billion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to precision oncology adoption, biomarker-based diagnostics, immunotherapy pipeline growth, early screening awareness, improved survival outcomes. Major trends in the forecast period include rising adoption of targeted therapies, increased use of combination treatment regimens, growth in early diagnostic technologies, expansion of immunotherapy applications, emphasis on personalized oncology care.

The rising prevalence of ovarian cancer is expected to drive growth in the epithelial ovarian cancer market in the coming years. Ovarian cancer originates in the ovaries, primarily affecting the epithelial cells that cover their surface. Factors contributing to the increasing prevalence include an aging population, greater awareness, higher detection rates, as well as genetic and lifestyle influences. Treatment for epithelial ovarian cancer is essential to target the most common and aggressive form of the disease, aiming to eliminate malignant cells and improve survival rates and patient outcomes. For example, in February 2024, the World Ovarian Cancer Coalition, a Canada-based non-profit organization, reported that by 2050, the global number of women diagnosed with ovarian cancer is expected to rise by over 55%, reaching 503,448. Annual deaths are projected to increase to 350,956, reflecting nearly a 70% rise from 2022. Therefore, the growing prevalence of ovarian cancer is expected to propel the epithelial ovarian cancer market forward.

Leading companies in the epithelial ovarian cancer market are focusing on developing innovative therapies, such as FRα-directed antibody-drug conjugates (ADCs), which specifically target folate receptor-alpha overexpressed on cancer cells. These ADCs deliver potent cytotoxic agents directly to cancer cells while minimizing damage to healthy tissue. For instance, in November 2024, AbbVie Inc., a US-based biopharmaceutical company, received European Commission approval for ELAHERE (mirvetuximab soravtansine), a targeted therapy for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE provides an effective treatment option for patients who have undergone up to three prior systemic regimens. It targets a biomarker present in approximately one-third of ovarian cancer patients, enhancing survival chances and improving quality of life. The approval also includes a companion diagnostic to identify eligible patients.

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen for $10.1 billion. The acquisition was intended to strengthen AbbVie’s oncology portfolio by adding ELAHERE, a targeted antibody-drug conjugate for treating platinum-resistant ovarian cancer. This move reduces reliance on older drugs and positions AbbVie strategically in the growing ADC market. ImmunoGen is a US-based company specializing in drugs for epithelial ovarian cancer.

Major companies operating in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Clovis Oncology Inc., Fujirebio Diagnostics Inc.

North America was the largest region in the epithelial ovarian cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epithelial ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the epithelial ovarian cancer market by increasing costs of imported oncology drugs, diagnostic imaging equipment, and targeted therapies. Hospitals and oncology centers in developed regions are most affected due to reliance on imported cancer treatments. These tariffs raise treatment costs by increasing expenses for chemotherapy, targeted agents, and advanced imaging, impacting patient access and healthcare budgets. However, they support domestic oncology drug manufacturing, strengthening regional capabilities for cancer therapeutics.

The epithelial ovarian cancer market research report is one of a series of new reports that provides epithelial ovarian cancer market statistics, including epithelial ovarian cancer industry global market size, regional shares, competitors with a epithelial ovarian cancer market share, detailed epithelial ovarian cancer market segments, market trends and opportunities, and any further data you may need to thrive in the epithelial ovarian cancer industry. This epithelial ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Epithelial ovarian cancer is the most common type of ovarian cancer, originating from the epithelial cells that form the outer layer of the ovary. Most often, it affects women over fifty. EOC is often asymptomatic in its early stages, leading to late diagnoses when the disease has already progressed. Symptoms, when present, may include abdominal bloating, pelvic pain, frequent urination, and changes in bowel habits.

The main types of treatments for epithelial ovarian cancer include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and surgery. Chemotherapy refers to a cancer treatment using drugs to destroy cancer cells or slow their growth. It offers various drugs such as platinum-based chemotherapy drugs, poly(adp-ribose) polymerase inhibitors, bevacizumab, and chemotherapeutic agents, and is used for early and advanced stages of cancer. It can be diagnosed using various methods such as imaging, biopsy, and blood tests, and is used by hospitals, clinics, and diagnostic laboratories.

The epithelial ovarian cancer market consists of revenues earned by entities by providing services such as genetic testing, supportive care services, telemedicine, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The epithelial ovarian cancer market also includes sales of diagnostic kits, targeted therapy drugs, chemotherapeutic agents, surgical instruments, and devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.